BNP Paribas Financial Markets Purchases New Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

BNP Paribas Financial Markets purchased a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 7,633 shares of the company's stock, valued at approximately $413,000.

A number of other hedge funds have also recently bought and sold shares of MLTX. Birchview Capital LP bought a new position in MoonLake Immunotherapeutics during the fourth quarter worth about $217,000. KLP Kapitalforvaltning AS acquired a new position in MoonLake Immunotherapeutics during the fourth quarter worth approximately $244,000. PEAK6 LLC acquired a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $271,000. Mariner LLC bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $272,000. Finally, Teacher Retirement System of Texas lifted its stake in MoonLake Immunotherapeutics by 18.4% during the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock worth $354,000 after purchasing an additional 1,013 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MLTX has been the subject of a number of recent research reports. Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price objective for the company in a report on Monday, May 19th. HC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. The Goldman Sachs Group decreased their price target on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Royal Bank of Canada assumed coverage on MoonLake Immunotherapeutics in a report on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price target for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $78.71.

MoonLake Immunotherapeutics Trading Up 2.0%

Shares of MLTX traded up $0.76 during mid-day trading on Thursday, reaching $38.93. 53,900 shares of the stock traded hands, compared to its average volume of 351,269. The firm has a fifty day moving average price of $38.33 and a 200 day moving average price of $44.20. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -30.18 and a beta of 1.31. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.13. During the same quarter in the prior year, the company earned ($0.22) EPS. On average, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.